Li An

Dr. Li An

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 June 2025 in Journal of Endocrinological Investigation
Verified
Journal Article
Closed access
PDF file
LALi An
Li An
JSJinjun Shi
Jinjun Shi
YPYe Pan
Ye Pan
YDYu Ding
Yu Ding
WGWEI GAO
WEI GAO
YWYao Wang
Yao Wang

25 May 2011 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
JZJi-Hong Zou
Ji-Hong Zou
LALi An
Li An
SCShi Chen
Shi Chen
LALi An
Li An

3 February 2019 in Journal of Diabetes Research
Verified
Journal Article
Open access
PDF file
KZKongbo Zhu
Kongbo Zhu
LQLinglin Qian
Linglin Qian
YLYanshan Lin
Yanshan Lin
LALi An
Li An
GMGuangjian Mu
Guangjian Mu
LRLiqun Ren
Liqun Ren
Increasing evidence shows that statins increase the risk of new-onset diabetes mellitus, but the exact mechanism is not clearly known. Free fatty acid receptor 1 (FFA1) has been recognized to mediate insulin secretion, and pioglitazone has direct effects on glucose-stimulated insulin secretion in addition to the reversion of insulin resistance. In this study, we found that atorvastatin decreased potassium-stimulated insulin secretion and inhibited the expression of FFA1, PDX-1, and BETA2/NeuroD in INS-1 cells. Further study demonstrated that pioglitazone prevented the impairment of insulin secretion induced by atorvastatin and enhanced the expression of FFA1, PDX-1, and BETA2/NeuroD reduced by atorvastatin in INS-1 cells. In addition, the preventive effect of pioglitazone on atorvastatin-induced impairment of insulin secretion and the enhancement of the expression of PDX-1 and BETA2/NeuroD was abolished by knockdown of FFA1 using siRNA or the PLC inhibitor, U-73122, respectively. Ultimately, FFA1 may mediate the atorvastatin-induced pancreatic β-cell dysfunction and pioglitazone may ameliorate this deleterious effect through the upregulation of FFA1 expression.

1 January 2025 in Open Life Sciences
Verified
Journal Article
Open access
YWYan Wang
Yan Wang
LALi An
Li An
The relationship between the NADPH oxidase p22phox C242T and susceptibility to ischemic stroke (IS) has been extensively studied, yet the findings from these studies remain inconsistent. To clarify this association, we conducted an updated meta-analysis of case-control studies. A comprehensive literature search of PubMed, Embase, and CNKI was performed on January 31, 2025. Studies exhibiting Hardy-Weinberg equilibrium (HWE) deviations in the control population were excluded from analysis. Pooled odds ratios (ORs) with corresponding 95 % confidence intervals (CIs) were calculated to evaluate the association across various genetic models. Our meta-analysis included 10 studies, comprising 3,422 cases and 3,410 controls. We found no significant association between the C242T polymorphism and IS susceptibility under any genetic model. Subgroup analyses stratified by ethnicity and IS type similarly revealed no significant increase in risk. Sensitivity analysis confirmed the stability of these pooled results. This updated meta-analysis suggests that the NADPH oxidase p22phox C242T polymorphism lacks a significant association with ischemic stroke risk. Nevertheless, larger and more diverse population studies are warranted to confirm these findings.